← All trials
NCT04727424
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 19, 2021
- Primary completion
- Feb 1, 2022
- Completion date
- Mar 1, 2022
- First posted
- Jan 27, 2021
- Last posted
- Jul 8, 2021
- Enrollment
- 3645
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cardresearch - Cardiologia Assistencial e de Pesquisa LTDALead sponsor
- McMaster UniversityStudy director
- McMaster UniversityCollaborator
- Eiger BioPharmaceuticalsCollaborator
- Cytel Inc.Collaborator
- Cardresearch - Cardiologia Assistencial e de Pesquisa LTDAStudy chair
- Fast GrantsCollaborator
- RainWater FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.